Upasani Ravindra B.,Harrison Boyd L.,Askew Benny C.,Dodart Jean-Cosme,Salituro Francesco G.,Robichaud Albert Jean
申请号：
US201816114791
公开号：
US2018362573(A1)
申请日:
2018.08.28
申请国别(地区):
美国
年份:
2018
代理人:
摘要：
Compounds are provided according to Formula (I):;;and pharmaceutically acceptable salts thereof, wherein Z is a group of the formula (i), (ii), (iii), (iv), or (v):;;and wherein L1, L2, L3, X1, X2, Y, RZ4, RZ5, RZ6, n, R1, R2, R3a, R3b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R14, R17, R19, R20, R23a, R23b, and R24 are as defined herein, and pharmaceutical compositions thereof. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions in mammals.
